Food and Drug Administration, HHS.
Final rule; correction.
The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The document was published with an inadvertent error. This document corrects that error.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Diane Sullivan, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171.End Further Info End Preamble Start Supplemental Information
In FR Doc. 2010-8467, appearing on page 19213, in the Federal Register of Wednesday, April 14, 2010, the following correction is made:
1. On page 19213, in the third column, the heading “RIN 0910-AF92” is corrected to read “RIN 0910-AF93”.Start Signature
Dated: September 13, 2010.
Acting Deputy Commissioner for Policy, Planning and Budget.
[FR Doc. 2010-23195 Filed 9-16-10; 8:45 am]
BILLING CODE 4160-01-S